Annovis Bio Inc. (NYSE: ANVS)

Introduction

Annovis Bio Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company’s lead candidate, buntanetap, is an orally administered small molecule designed to inhibit multiple neurotoxic proteins.

Stock Snapshot (2025-06-04)

• Price: $3.33
• Change: +27.58%
• Volume: 977,035
• 52-Week Range: $1.11 – $17.88
• Market Cap: $64.9 M
• Beta (5Y): 1.62

---

Corporate Structure

• Headquarters: Malvern, Pennsylvania
• Founded: 2008
• Leadership: Maria Maccecchini, Ph.D. (Founder & CEO)
• Employee Range: 2–10 (per LinkedIn)
• Shares Outstanding: 19.5 million (post-offering)
• NYSE Notice: As of March 26, 2025, Annovis received a continued-listing noncompliance notice under Section 802.01B due to an average market capitalization of $37.9 million, below the $50 million requirement, and stockholders’ equity of $9.3 million.

---

Recent Developments and News

Clinical Pipeline & Milestones

• Pivotal Phase 3 AD Study

  • Launch: Q1 2025
  • Design: Single 6-month symptomatic assessment and 12-month disease-modifying assessment
  • Readouts: Symptomatic data expected in mid-2026; disease-modifying data anticipated in mid-2027

• Phase 3 PD Study

  • Completion: Involved 471 participants with a diagnosis of more than 3 years
  • Findings: Improvements noted in MDS-UPDRS Part II & III; cognitive decline (MMSE) was halted over a 6-month period

• Phase 2a AD Studies

  • Duration: 20–28 days
  • Doses & Results:
    • 7.5 mg (p=0.013), 15 mg (p=0.001), 30 mg (p<0.001) versus baseline
    • 15 mg (p=0.042), 30 mg (p=0.015) versus placebo
    • APOE4 carriers demonstrated a 3–4 point improvement in ADAS-Cog11

• Patent Grant: A U.S. patent was issued for the use of buntanetap in acute brain and nerve injuries, enhancing existing coverage in Europe and Japan.

• FDA Protocol Acceptance: A single 6/18-month protocol was accepted in February 2025.

Corporate & Financial Events

• NYSE Continued-Listing Notice: Issued on March 26, 2025, with a plan required within 45 days.
• Public Offering Pricing: On February 3, 2025, an underwritten public offering included 5.25 million shares and 5.25 million warrants at $4.00 per unit, with warrants exercisable at $5.00 for a five-year term.
• Offering Close: The offering closed on February 4, 2025, with gross proceeds amounting to $21 million, increasing the share count from 14.1 million to 19.5 million.

---

Financial & Strategic Analysis

Q4 2024 vs Q4 2023; FY 2024 vs FY 2023

Metric	Q4 2024	Q4 2023	FY 2024	FY 2023
R&D Expenses	$5.0 M	$8.9 M	$20.0 M	$38.8 M
G&A Expenses	$1.7 M	$1.5 M	$6.7 M	$6.2 M
Net Loss per Share (Basic)	$0.43	$2.24	$2.02	$6.23
Cash & Equivalents (Dec 31)	$10.6 M	$5.8 M	—	—

• Cost Management: R&D expenses decreased by 44% in Q4 and 49% for FY; G&A expenses remained stable.
• Profitability: Net loss per share improved by 81% in Q4 and 68% for FY.
• Liquidity: Cash position of $10.6 million supports operations into Q4 2025 (inclusive of the $21 million offering).
• Dilution: Share count increased by 38.3%.

Strategic Positioning

• Differentiation: Buntanetap is an oral therapy that targets multiple neurotoxic proteins compared to single-target biologics.
• Regulatory Path: Sequential readouts may facilitate accelerated symptomatic approval followed by a disease-modifying claim.
• Intellectual Property Strength: Patent coverage has been expanded in key markets for acute indications.

---

Market Position & Industry Context

• Addressable Market: Alzheimer’s and Parkinson’s diseases represent significant unmet needs in the aging population.
• Early Intervention Trend: There is a growing consensus on the benefits of treating early-stage neurodegeneration for improved outcomes.
• Competitive Landscape: Buntanetap competes with monoclonal antibodies and other small molecules, with oral dosing providing patient convenience.
• Challenges: Industry-wide hurdles include clinical trial attrition, funding requirements, and regulatory compliance.

---

tl;dr

• February 4, 2025: $21 million public offering closed; shares rose to 19.5 million.
• Q1 2025: Pivotal Phase 3 Alzheimer’s study is underway; symptomatic data is due in mid-2026, disease-modifying data in mid-2027.
• Phase 3 PD Study: 471 participants demonstrated motor and cognitive benefits over six months.
• March 26, 2025: NYSE issued a continued-listing noncompliance notice (average market cap $37.9 million versus $50 million requirement).
• Cash Position: $10.6 million as of December 31, 2024, funding operations into Q4 2025.